866-997-4948(US-Canada Toll Free)

Brain Tumor - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 94 Pages


Global Markets Directs, \'Brain Tumor Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Brain Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Tumor. 

Brain Tumor Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Brain Tumor.
  • A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Brain Tumor pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Brain Tumor.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Brain Tumor pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Brain Tumor Overview
Therapeutics Development
An Overview of Pipeline Products for Brain Tumor
Brain Tumor Therapeutics under Development by Companies
Brain Tumor Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Brain Tumor Therapeutics – Products under Development by Companies
Brain Tumor Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Brain Tumor Therapeutics Development
United Therapeutics Corporation
Antigenics, Inc.
YM BioSciences Inc.
Bayer AG
Telik, Inc.
Nanobiotix
InDex Pharmaceuticals AB
DNA Therapeutics S.A.
NovaRx Corporation
Hutchison MediPharma Limited
Advantagene, Inc.
Advanced Cancer Therapeutics
Celtic Pharmaceutical Holdings L.P.
DEKK-TEC, Inc.
Brain Tumor – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HMPL-813 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DIMS-0150 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TLK-58747 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
8H9-MAb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
corticorelin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
corticorelin acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
irinotecan hydrochloride + sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
3-PO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LXY-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADV-TK - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mafosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nimotuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Glionix - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Poly ICLC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
survivin peptide vaccine + [montanide ISA-51] + [sargramostim] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
4-Hydroperoxyifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAL-083 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TP-0903 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NP-150 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Neural Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DT-01 + [temozolomide] + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bispecific T-Cell Engager - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bay-846 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Triaryl NADPH Oxidase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brain Tumor Therapeutics – Drug Profile Updates
Brain Tumor Therapeutics – Discontinued Products
Brain Tumor Therapeutics - Dormant Products
Brain Tumor – Product Development Milestones
Featured News & Press Releases
Nov 05, 2012: Celldex To Present Clinical Data On Rindopepimut At Society For Neuro-Oncology 17th Annual Scientific Meeting And Education Day
Jun 27, 2012: Celtic Pharma Announces Presention Of Phase I/II Study Results Of Xerecept At International Symposium For Pediatric Neuro-Oncology
May 22, 2012: Celtic Pharma Successfully Completes Phase I/II Study Of Xerecept In Pediatric Patients With Cerebral Tumors
Oct 03, 2011: Celtic Pharma Completes Enrollment In Dose Tolerance Trial Evaluating Xerecept In Pediatric Patients With Primary And Metastatic Brain Tumors
Aug 18, 2011: Cell Therapeutics Announces Enrollment Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors
Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors
Feb 02, 2011: Antisense Pharma Receives Approval For Clinical Studies In South Korea And Taiwan In Malignant Brain Tumors
Nov 02, 2010: Antisense Pharma’s Trabedersen In Malignant Brain Tumors: Phase IIb Data Published In Neuro-Oncology
Oct 29, 2010: Novartis Drug Afinitor Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis.

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 

List of Table


Number of Products Under Development for Brain Tumor, H1 2013 10
Products under Development for Brain Tumor - Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 16
Comparative Analysis by Late Stage Development, H1 2013 17
Comparative Analysis by Mid Clinical Stage Development, H1 2013 18
Comparative Analysis by Early Clinical Stage Development, H1 2013 19
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 20
Products under Development by Companies, H1 2013 21
Products under Development by Companies, H1 2013 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2013 23
United Therapeutics Corporation, H1 2013 24
Antigenics, Inc., H1 2013 25
YM BioSciences Inc., H1 2013 26
Bayer AG, H1 2013 27
Telik, Inc., H1 2013 28
Nanobiotix, H1 2013 29
InDex Pharmaceuticals AB, H1 2013 30
DNA Therapeutics S.A., H1 2013 31
NovaRx Corporation, H1 2013 32
Hutchison MediPharma Limited, H1 2013 33
Advantagene, Inc., H1 2013 34
Advanced Cancer Therapeutics, H1 2013 35
Celtic Pharmaceutical Holdings L.P., H1 2013 36
DEKK-TEC, Inc., H1 2013 37
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 43
Brain Tumor Therapeutics - Drug Profile Updates 77
Brain Tumor Therapeutics - Discontinued Products 82
Brain Tumor Therapeutics - Dormant Products 83
Brain Tumor Therapeutics - Dormant Products (Contd..1) 84

List of Chart


Number of Products under Development for Brain Tumor, H1 2013 10
Products under Development for Brain Tumor - Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 17
Mid Clinical Stage Products, H1 2013 18
Early Clinical Stage Products, H1 2013 19
Discovery and Pre-Clinical Stage Products, H1 2013 20
Assessment by Monotherapy Products, H1 2013 38
Assessment by Combination Products, H1 2013 39
Assessment by Route of Administration, H1 2013 40
Assessment by Stage and Route of Administration, H1 2013 41
Assessment by Molecule Type, H1 2013 42
Assessment by Stage and Molecule Type, H1 2013 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *